BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Oxford Immunotec Limited Raises $28 Million to Accelerate Commercial Sales Ramp


6/18/2012 8:04:37 AM

OXFORD, England & MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Oxford Immunotec, a medical diagnostic company developing tests in the fields of infectious and immunological disease, announced today that it has raised a total of $28m in a new equity financing. The round was led by new investors Imperial Innovations and Invesco Perpetual and supported by existing shareholders, including Clarus, New Leaf, DFJ Esprit, Wellington, SPARK Ventures, the Dow Chemical Company, NTEC, Kaiser Permanente Ventures and the University of Oxford. Oxford Immunotec has now completed five institutional funding rounds totaling approximately $110 million since its establishment in 2002.

The proceeds from this financing will be used to expand sales & marketing of Oxford Immunotec’s lead product, the T-SPOT®.TB test for diagnosing latent TB infection, as well as for the development and commercialization of new products focused on infectious and immunological disease.

Susan Searle, Chief Executive Officer, Imperial Innovations, said: “Oxford Immunotec is a well-run, high-growth company in an exciting space. This funding provides it with the capital to expand its operations in key markets and enables a UK university spin out to become a truly multinational business.”

Dr. Peter Wrighton-Smith, Chief Executive Officer, Oxford Immunotec commented: “This $28m funding exceeded our funding goal and is further validation of the market opportunity we are pursuing, the strength of our lab-based US business model and our early progress in penetrating that market. This funding will help us to expand sales & marketing at a faster rate, to penetrate new geographies and to accelerate the development and commercialization of other assays for our expanding customer base.”

About Oxford Immunotec

www.oxfordimmunotec.com

Oxford Immunotec Ltd., a global immunology-focused diagnostic company, is headquartered near Oxford, UK; its US operations are based in Marlborough, MA. The company is developing novel new tests in the fields of infectious and immunological disease based primarily on its patented T-SPOT® technology, the first FDA-approved method for directly quantifying antigen-specific T cells.

T-SPOT technology is a simple and extremely accurate method of studying a person’s cellular immune response and, as such, provides a unique methodology to diagnose and monitor diseases driven by a T cell response.

Oxford Immunotec’s primary product, the T-SPOT.TB test, is one of two Interferon-gamma release assays (IGRAs) which detect latent TB infection and are replacing the 90-year old tuberculin skin test currently used for this purpose. The World Health Organisation1 estimated in 2006 that 50 million latent TB screening tests were performed each year, representing a greater than $1bn per annum market opportunity for TB testing globally. IGRAs are now endorsed in clinical guidelines in over 20 countries and the T-SPOT.TB test has now received regulatory approval in over 40 countries worldwide, including the US, Europe and China. In the US, the T-SPOT.TB test has its own CPT® code (86481) with recently increased CMS reimbursement of approximately $106/test. The T-SPOT.TB test is also covered in various other clinical lab fee schedules around the world.

As well as developing & selling tests in kit form, Oxford Immunotec also runs a testing laboratory business in both the US and the UK (Oxford Diagnostic Laboratories) designed to provide unparalleled levels of expertise, service, turnaround time and simplicity for physicians wanting to access immunological tests such as the T-SPOT.TB test.

T-SPOT and the Oxford Immunotec logo are registered trademarks of Oxford Immunotec Ltd.

CPT is a registered trademark of the American Medical Association

1 WHO. Diagnostics for tuberculosis : global demand and market potential. 2006

Contact:

At Oxford Immunotec: Dr Peter Wrighton-Smith, CEO

Tel: +44 (0)1235 442780

Fax: +44 (0)1235 442781

Email: info@oxfordimmunotec.com




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->